Posted by Michael Wonder on 13 Nov 2016
ICER to review drug treatments for osteoporosis in upcoming report
11 November 2016 - The ICER will develop a report assessing the comparative clinical effectiveness and value of emerging drug therapies for the treatment of osteoporosis to inform a meeting of the California Technology Assessment Forum in June 2017.
While awaiting further discussion with patient groups, clinical experts, and other stakeholders to help develop a formal scope for this review, our preliminary intent is to evaluate the emerging treatments abaloparatide and romosozumab, with potential comparisons to denosumab and teriparatide. We do not currently envision including within the scope of this review other drugs or forms of treatment such as exercise, dietary supplements, vitamins or calcium, hormones, selective estrogen receptor modulators, or bisphosphonates.
Additional information on the preliminary list of treatments to be reviewed will be posted as part of a draft scoping document scheduled to be released for public comment on 5 December 2016.
